Minnesota Glomerular Disease Program
Front Row from Left to Right: Lama Ghazi, Michelle Hintz, Surabhi Thakar, Charlotte Quinton
Back Row from Left to Right: Rana Leed, Patrick Nachman, Katti Woerner, and Elizabeth Miller
Mission
To provide patients with glomerular disease with expert, individualized care and access to clinical trials.
Covered Diseases
- Any glomerular disease, including (but not limited to):
- Focal Segmental Glomerulosclerosis (FSGS)
- Membranous nephropathy
- Minimal change disease
- IgA nephropathy
- Immune complex mediated diseases
- C3 Glomerulopathy
- Fibrillary Glomerular Disease
- Cryoglobulinemia
- Anti-Glomerular Basement Membrane (anti-GBM) Disease
- Alport Syndrome
- Thin basement membrane disease
- Vasculitis
- Lupus Nephritis
- For systemic diseases associated with Systemic Lupus Erythematosus or vasculitis, please visit the Minnesota Multidisciplinary Vasculitis Program webpage
Goals
- Provide patients with glomerular disease with expert care which is organized, streamlined and efficient.
- Provide community physicians and providers with a portal for efficient peer-to-peer consultation or referral.
- Provide patients with access to cutting-edge clinical trials.
- Facilitate translational research.
- Provide a venue for health care providers training in the care of patients with glomerular disease.
Our Team
Physicians
Clinical & Translational Research Team
- Joy Bolea RN, MS - Clinical Research Coordinator
- Mary McDonald, RN, CCRP - Clinical Research Coordinator
- Scott Rajala, CCRP - Clinical Research Coordinator
Ongoing Clinical Trials
FOCAL SEGMENTAL GLOMERULOSCLEROSIS (FSGS)
Phase 2a Trial
A Phase 2a Multiple Ascending, Placebo-Controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GFB-887, a TRPC5 Channel Inhibitor, in Patients With Diabetic Nephropathy, Focal Segmental Glomerulosclerosis, and Treatment-Resistant Minimal Change Disease
Principal Investigator
Patrick Nachman, MD
Study Coordinator
Mary McDonald, RN, CCRP
mcdo0664@umn.edu
IGA NEPHROPATHY
Phase 3 Trial
A Randomized, Double-blind, Placebo-Controlled Study to Evaluate Efficacy and Safety of Nefecon in Patients with Primary IgA (Immunoglobulin A) Nephropathy at Risk of Progressing to End-stage Renal Disease (NefIgArd)
Principal Investigator
Surabhi Thakar, MD
Co-Investigator
Katti Woerner, MD
Study Coordinators
Mary McDonald, RN, CCRP
mcdo0664@umn.edu
Phase 3 Trial
A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Safety and Efficacy of OMS721 in Patients with Immunoglobulin A (IgA) Nephropathy (ARTEMIS - IGAN)
Principal Investigator
Patrick H. Nachman, MD
Study Coordinators
Mary McDonald, RN, CCRP
mcdo0664@umn.edu
MEMBRANOUS NEPHROPATHY
Phase 2 Trial
Efficacy of Belimumab and Rituximab Compared to Rituximab Alone for the Treatment of Primary Membranous Nephropathy (REBOOT)
Principal Investigator
Study Coordinators
Mary McDonald, RN, CCRP
mcdo0664@umn.edu
Joy Bolea, RN, MS
jbolea@umn.edu